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Abstract
We previously discovered a positive allosteric modu-
lator (PAM) of the metabotropic glutamate receptor
subtype5(mGlu5)termed4N-{4-chloro-2-[(1,3-dioxo-
1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxy-
benzamide (CPPHA) that elicits receptor activation
through a novel allosteric site on mGlu5, distinct from
the classical mGlu5 negative allosteric modulator
(NAM) MPEP allosteric site. However, a shallow
structure-activity relationship (SAR), poor physio-
chemical properties, and weak PAM activity at rat
mGlu5 limited the utility of CPPHA to explore allos-
tericactivationofmGlu5atanon-MPEPsite.Thus,we
performed a functional high-throughput screen (HTS)
and identified a novel mGlu5 PAM benzamide scaffold,
exemplified by VU0001850 (EC50 =1 . 3μM, 106%
Glumax) and VU0040237 (EC50 = 350 nM, 84% Glu
Max). An iterative parallel synthesis approach delivered
22 analogues, optimized mGlu5 PAM activity to afford
VU0357121 (EC50 =3 3n M ,9 2 %G l u max), and also
revealed the first non-MPEPsite neutral allosteric ligand
(VU0365396). Like CPPHA, PAMs within this class do
not appear to bind at the MPEP allosteric site based on
radioligand binding studies. Moreover, mutagenesis
studies indicate that VU0357121 and related analogues
bind to a yet uncharacterized allosteric site on mGlu5,
distinct from CPPHA, yet share a functional interaction
with the MPEP site.
Keywords:mGlu5,metabotropic,glutamate,allosteric,
potentiator
G
lutamate is the major excitatory neurotrans-
mitter in the mammalian central nervous
system (CNS). It plays important roles in
virtually all major CNS circuits by acting through
ionotropic glutamate receptors (iGluRs), as well as
metabotropic glutamate (mGlu) receptors. The eight
mGluR subtypes arefamilyC G-proteincoupledrecep-
tors (GPCRs) that are divided into three groups based
onsequencehomologyandcouplingtosignaltransduc-
tioncascades.GroupIincludesmGlu1andmGlu5;these
receptors couple to GRq and induce increases in intra-
cellular calcium. Group II (mGlu2and mGlu3)a n dg r o u p
III (mGlu4,m G l u 6,m G l u 7, and mGlu8) receptors cou-
pletoGRi/oandinhibitcAMP formation(1).Thefamily
C GPCRs are characterized by a large bilobed (termed
venus fly trap) extracellular ligand binding domain
where the endogenous ligand glutamate and other
orthosteric ligands bind (Figure 1A). Because of the
highly conserved nature of the orthosteric binding site,
ligands that modulate receptorfunction atthissite have
poor subtype selectivity among the mGlu receptors. An
alternative approach to targeting the highly conserved
orthostericglutamate site istodevelopcompounds that
act at allosteric sites on mGlu receptors that are re-
moved from the orthosteric site in the heptahelical
transmembrane domain and may be less highly con-
served.Thisapproachisprovinghighlysuccessfulformul-
tiple GPCRs. Negative allosteric modulators (NAMs)
were the first allosteric ligands reported for the mGlu
receptors and have been described for mGlu1 and
mGlu5 (2, 3); moreover, positive allosteric modulators
(PAMs),molecules thatbindatanallostericsite,donot
activatethereceptordirectlybutpotentiateactivationof
the receptor by the orthosteric agonist glutamate, have
been reported for mGlu2,m G l u 4, and mGlu5 (4).
Recent anatomical, cellular, molecular, and beha-
vioral findings suggest that selective activators of the
metabotropic glutamate receptor subtype 5 (mGlu5)
may provide a novel strategy for the treatment of the
psychoticsymptomsandcognitiveimpairmentsobserved
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in individuals with neuropsychiatric disorders (5-7).
However, it has been historically difficult to produce
agonists of mGlu5 that are selective for this subtype as
comparedtoothermGlureceptors.Recently,ourlabora-
tory and others have made major breakthroughs in this
area by developing selective positive allosteric modula-
tors (PAMs) of this receptor. MPEP 1is the prototypical
mGlu5 NAM with a well characterized allosteric binding
site (Figure 1B; see references 2, 8,a n d9). Several dis-
tinct chemotypes have been identified that function as
mGlu5 PAMs and are exemplified by DFB 2,M P P A3,
CDPPB 4/VU-29 5, and the ADX series (ADX47273 6,
(S)-FTOPM 7,a n d( S)-FPOPM 8)( 9-12). All of these
PAMs potentiate mGlu5-mediated responses by binding
to the well-characterized, negative allosteric modulator
MPEP binding site. Interestingly, CPPHA 9 is the only
known mGlu5PAM that does not bind to the MPEP site
and acts via a unique site on the receptor to potentiate
mGlu5 responses (13, 14). These data suggest that multi-
ple allosteric sites exist on mGlu5.A l s o ,C D P P B ,
ADX47273, and (S)-FTOPM display intrinsic agonist
activity at moderate to high concentrations in Chinese
hamster ovary (CHO) or human embryonic kidney
(HEK293) cells expressing rmGlu5,w h e r e a sM P P A ,
DFB,(S)-FPOPM,andCPPHAhavenoeffectonmGlu5
alone, and only potentiate responses of the receptor to
glutamate(i.e.,purePAM)(10,11,13,15).Inaddition,we
have shown that CPPHA and DFB display differential
modulatory function on mGlu5-mediated phosphoryla-
tion of extracellular signal-regulated kinases 1 and 2
(ERK1/2) (16). Together, these findings indicate that
mGlu5PAMscanhavedifferentialeffectsondownstream
receptor trafficking by virtue of the allosteric site the
ligand occupies to exert conformational changes leading
to potentiation. Thus, it will prove critically important to
identify additional novel classes of mGlu5 PAMs and
allosteric binding sites to further our understanding of
differential mGlu5 potentiation and receptor trafficking.
CPPHA, due to its unique allosteric binding site
and pharmacology, has the potential to serve as an
important pharmacological tool to further investigate
functional selectivity among classes of mGlu5 PAMs.
Unfortunately, due to diminished potency on rodent
mGlu5,shallowSAR,andpoorphysiochemicalproperties,
CPPHA is of limited utility to translate into in vivo
studies (17). Here, we describe the identification, SAR
andinvitropharmacologicalcharacterizationofanovel
chemical class of mGlu5 PAMs that are reminiscent of,
yetdistinctfrom,CPPHAthatactivatemGlu5at a non-
MPEP and non-CPPHA allosteric site. Moreover, this
new series ofmGlu5 PAMs, representedbyVU0357121
(EC50 = 33 nM, 92% Glumax), possess potent acti-
vity on the rat receptor. This effort also identi-
fied VU0365396, the first non-MPEP neutral allosteric
ligand.
Results and Discussion
A number of significant issues have hampered the
basic science efforts driving mGluR research across all
receptor subtypes: (1) a lack of truly selective tool
compounds to clearly elucidate the physiological role
of given subtypes, (2) receptor trafficking phenomenon
Figure 1. (A) Schematic illustration of the structure of a metabo-
tropicglutamatereceptor.(B)StructuresofknownmGlu5allosteric
ligands (NAMs and PAMs).
Figure 2. Benzamide compounds are able to potentiate the calcium
mobilization response of mGlu5 to glutamate. Raw traces show the
effect of a fixed concentration (10 μM) of test compound or vehicle
when added to calcium-sensitive dye-loaded cells and allowed to
incubatefor5min.Asuboptimal(EC20)concentrationofglutamate
was added and the calcium response measured by the FDSS plate
reader. Responses are expressed as a fluorescence ratio.r2010 American Chemical Society 704 DOI: 10.1021/cn100051m|ACS Chem. Neurosci. (2010), 1, 702–716
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bydifferentallostericligandsandbyreceptoractivation
at different allosteric binding sites, and (3) subtle mo-
lecular switches that elicit alternate modes of pharma-
cology. In order to develop an mGlu5 PAM that could
be developed as a potential therapeutic agent, we must
first understand the functional relationship between
distinctallostericbindingsitesanddownstreamreceptor
trafficking. In order to accomplish this, it will be
importanttounderstandthesimilarities anddifferences
between novel mGlu5 PAMs that act at different allos-
teric sites.
Discovery of a Novel Benzamide Class of
mGlu5 PAMs by HTS
Our laboratory performed a functional high-
throughputscreen (HTS) (18-20) that led tothe identi-
fication of about 20 structural classes of mGlu5 PAMs.
The present study focuses on a novel benzamide chemi-
cal scaffold that was identified in that screen. Sixty-five
compoundswereidentifiedthatbelongtothisstructural
class, and 10 were found to have high potencies with
EC50 values e1 μM from HTS stock solutions. This
class is of particular interest because these compounds
share a benzamide backbone that is similar to that of
CPPHAyetaredistinct.Thesecompoundsdisplaylittle
intrinsic mGlu5 agonist activity in the calcium mobi-
lization assay and induce a robust enhancement of
the response to a suboptimal concentration (EC20)o f
glutamate (Figure 2). To test their PAM activity,
HEK293 cells expressing rat mGlu5 were preloaded
with calcium-sensitive fluorescent dye and received
vehicle or compound (10 μM ) ,f o l l o w e db ya nE C 20
concentration of glutamate 5 min later. Receptor-
induced calcium mobilization responses were moni-
tored using Functional Drug Screening System (FDSS,
Hamamatsu, Japan).
Design, Synthesis, and SAR of Benzamide
Analogues
As previously stated, the lead optimization pro-
gram that led to the discovery of CPPHA faced several
challenges, making it difficult to develop compounds
r e l a t e dt oC P P H At h a tr e t a i n e da c t i v i t yo nr o d e n t
mGlu5 (17). The three most potent compounds within
thebenzamidechemicalclass(VU0001850,VU0003712,
an dVU00 40 23 7)ar esh o wni nF ig u re3 .Wit hth eid en ti -
fication of our three main hits from the screen, we had
the opportunity to determine whether slight modifica-
tions to theirchemical structures wouldlead to tractable
SAR for rat mGlu5 or afford modulation in the mode of
mGlu5pharmacology.Forchemicalleadoptimization,we
elected to employ a parallel synthesis approach in which
we resynthesized the three initial hits along with a library
of 22 analogues to obtain an initial understanding of the
SAR in a 25-member library of analogues 10 (Figure3A).
Thefirstsetofanaloguesvariedboththearyl/heteroaryl
amide (blue) as well as different ethers (green). The
chemistry involved treatment of a p-alkoxy benzoyl
chloride 11 and an aryl/heteroaryl amine 12 to provide
analogues10orthecorrespondingbenzoicacid13could
be coupled to 12 under standard carbodiimide condi-
tions to delivers analogues 10 (Figure 3B). All com-
pounds were purified by mass-directed preparative
HPLC to >98% purity.
These novel analogues were assayed in a single-point
screen, along with the three original hits, to determine
theirabilitytopotentiateasuboptimalconcentrationof
glutamate using the FlexStation fluorometric imaging
plate reader from Molecular Systems. HEK293 cells
expressing mGlu5 were incubated with a fixed concen-
tration of test compound for 109 s and then stimulated
with an EC20 concentration ofglutamate. At 10 μM, all
three of the original hits (VU0001850, VU0003712, and
VU0040237), as well as three of the novel analogues
(VU0357121, VU0365393, and VU0125936), poten-
tiated the response to suboptimal glutamate concentra-
tions above a 50% response, which was used as a cutoff
reference (Figure 4A). Screening the compounds at a
concentration of 1 μM revealed that two of the original
hits (VU0001850 and VU0040237) as well as two of
Figure 3. Design and synthetic strategy for chemical lead optimi-
zation ofmGlu5 PAM HTS hits. (A) Structures of mGlu5 PAM hits
and general library design strategy. (B) General synthetic
approaches employed for iterative library synthesis.r2010 American Chemical Society 705 DOI: 10.1021/cn100051m|ACS Chem. Neurosci. (2010), 1, 702–716
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the newly synthesized compounds (VU0357121 and
VU0125936) potentiated the response to glutamate at
submicromolar concentrations (Figure 4B), and these
compounds were chosen for further analysis as mGlu5
PAMs. As we had previously seen with CPPHA, SAR
was quite shallow for this new series, with few active
PAMs.
To further evaluate the compounds that were identi-
fied as potent mGlu5 PAMs (VU0001850, VU0040237,
VU0357121, and VU0125936), we determined their
ability to potentiate mGlu5 responses to glutamate in
two separate calcium mobilizationassays. First,thetest
compound’s concentration-response relationships
were examined by incubating mGlu5-expressing cells
with increasing concentrations of compound in the
presence of a fixed suboptimal concentration of gluta-
mate (EC20).
Figure5showstheconcentration-responserelation-
ships for these compounds, and compound potencies
ranged from ∼33 nM to 1 μM. A second measure of
potentiation was performed to assess the ability of the
compounds to increase the potency of a glutamate
concentration-response curve (fold-shift assay). This
is measured as a leftward shift of the glutamate con-
centration-response curve (CRC) and decrease in the
EC50 of glutamate in the presence of test compound
as compared to a glutamate concentration-response
curve in the presence of vehicle only. HEK293 cells
expressingmGlu5werepretreatedwithvehicleorafixed
concentration (12.5 μM) of the mGlu5 PAM, followed
by increasing concentrations of glutamate. The test
compounds caused 2- to ∼6-fold shifts in the glutamate
concentration-response curve at mGlu5 (Figure 6),
providing further evidencefortheirability topotentiate
mGlu5-mediated responses to glutamate.
Figure 7 highlights the SAR for the benzamide series
afteroneroundoflibrarysynthesis.TheinitialHTShits
VU0001850 and VU0040237 were found to possess
EC50 values of 1.3 μM and 350 nM on rat mGlu5,
respectively. Both VU0001850 and VU0040237 poten-
tiatedtheresponsetotheEC20 glutamate concentration
to 106% and 84% of the response to a maximal
concentration of glutamate, respectively (% Glumax),
and induced leftward shifts (∼5.2  and ∼3.9 ,r e s -
pectively) of the glutamate CRC (Figure 7A). The two
new analogues, VU0357121 and VU0125936, repre-
sented improvements over the HTS leads. Addition of
a second fluorine into the 4-position of VU0040237
provided VU0357121 (EC50 =3 3n M ,9 2 %G l u max,
and ∼2.6-fold shift) and a 10-fold increase in potency
over the HTS hit. Similarly, homologation of the
n-propyletherinVU0001850toann-butyletheranalogue
VU0125936 provided an increase in rat mGlu5 potency
(EC50 = 664 nM, 112% Glumax,a n d∼5.8-fold shift).
Again, further libraries resulted in no significant
active mGlu5 PAMs, and the SAR was highly reminis-
cent of the CPPHA SAR. As depicted in Figure 7B,
alternate chain lengths and/or cyclic constraints in the
ether linkage abolished PAM activity. Minor modifica-
tions, such as N-alkylation of the secondary amide, led
toinactiveanalogues.Finally,arylsubstitutionotherthan
fluorine and alternative heterocycles for the 2-pyridyl
moiety also resulted in no measurable PAM activity.
These data, coupled with the structural similarities of
these compounds to CPPHA, led us to speculate that
this series of mGlu5 PAMs may bind at either the
CPPHA site or an overlapping, shallow allosteric site,
asMPEP-sitePAMsgenerallyaffordmorerobustSAR.
VU0357121 and Analogues Are Selective for
mGlu5 Relative to Other mGluR Subtypes
Before using these compounds to explore mGlu5 allos-
teric sites, it was necessary to ensure that they were in fact
selective for mGlu5 relative to other mGluR subtypes.
All four compounds were tested against mGlu receptors
1-4,6,7,and8,anddisplayedsimilarselectivityprofiles;
Figure 4. HTS hits and several novel analogues potentiate mGlu5-
mediated effects on calcium mobilization. The compounds were
screened for their ability to potentiate a suboptimal concentration
of glutamate when HEK cells were pretreated with a fixed concen-
tration of test compound at either (A) 10 μM or (B) 1 μM. The red
lines identify those compounds that are able to potentiate the
glutamate-induced response above 50% of the maximal response.
Data were normalized to the average maximal response obtained
from each experiment as determined by 100 μM glutamate. Data
were obtained from three separate experiments, each performed in
triplicate, and are expressed as the mean ( SEM.r2010 American Chemical Society 706 DOI: 10.1021/cn100051m|ACS Chem. Neurosci. (2010), 1, 702–716
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therefore, data for the most potent PAM, VU0357121,
is highlighted as representative (Figure 8). First, we
looked at the effects of the compounds on mGlu1
because this receptor has the closest homology to
mGlu5(1),whichleadsto ahighdegreeofcross-activity
of compounds. Fold-shift studies were performed as
described above, except that HEK293 cells expressing
ratGlu1wereused.Thesecompoundsdidnotcauseany
shift in the glutamate concentration-response curve
when added at 30 μM and only induced a slight depres-
sion in the maximum glutamate response, demonstrat-
ing a lack of PAM activity at mGlu1 (Figure 8). Our
laboratory recently developed an assay that detects the
activity of compounds that interact with Gi/o-coupled
GPCRs, such as the group II and III mGlu recep-
tors (21). This assay measures thallium flux mediated
Figure 5. Test compounds are able to potentiate the calcium flux response of mGlu5 to a suboptimal (EC20) concentration of glutamate.
Concentration-response relationships were generated by incubating cells with increasing concentrations of test compound, followed by
stimulation with EC20 glutamate. Data were obtained from three separate experiments, each performed in duplicate, and are expressed as the
mean ( SEM. Data were normalized to the average maximum response obtained from each experiment as determined by 100 μM glutamate.
Concentration-response curves were generated by nonlinear curve fitting.
Figure 6. Benzamide PAMs induce a leftward shift in the glutamate response curveat mGlu5. The 2- to 6-fold leftward shifts induced by these
compoundsindicateanenhancementoftheresponseofmGlu5toglutamate.Concentration-responserelationships weregeneratedbyadding
a fixed concentration (12.5 μM) of test compound to cells, followed by increasing concentrations of glutamate. Data were analyzed using
nonlinear regression, providingEC50values foreachcurve.Datawereobtained fromthreeseparate experiments,each performedinduplicate,
andareexpressedasthemean(SEM.Datawerenormalizedtotheaveragemaximumresponseobtainedfromeachexperimentasdetermined
by 100 μM glutamate.r2010 American Chemical Society 707 DOI: 10.1021/cn100051m|ACS Chem. Neurosci. (2010), 1, 702–716
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by G-protein-regulated inwardly rectifying potassium
channels (GIRKs). By performing fold-shift assays
using HEK/GIRK cells that stably express either mGlu
2, 3, 4, 6, 7, or 8, we found that the test compounds did
not modulate the response of any of these receptors to
agonist, providing more evidence for their subtype
selectivity(Figure8).Thesestudiesconfirmedthatthese
compounds are highly selective as PAMs of mGlu5 and
are infactinactive orvery weakly antagonizing at other
mGlu receptor subtypes.
VU0357121 and Analogues Do Not Bind at the
MPEP Allosteric Site
Because of the structural similarity between these
novel mGlu5 PAMs and CPPHA and the shallow
SAR, we hypothesized that they might interact with a
site on the receptor that is distinct from the MPEP
bindingsite.Inordertotestthishypothesis,weassessed
the ability of these test compounds to compete for
binding of the radiolabeled MPEP analogue [
3H]3-
methoxy-5-(pyridin-2-ylethynyl)pyridine) ([
3H]methoxy-
PEPy) (22) to evaluate their interaction with the allosteric
MPEP site on mGlu5. The radioligand was added to
membranes prepared from HEK293 cells stably expres-
sing mGlu5 with or without the test compound, and
reactions were allowed to incubate for 1 h. It was found
that,unlikeMPEP (Ki=35(10.4nM), test compounds
did not inhibit steady state [
3H]methoxyPEPy binding at
concentrations of up to 100 μM, 3 orders of magnitude
higher than those required for their PAM activity, sug-
gesting that the ability of these agents to enhance gluta-
matesensitivityofmGlu5islikelyduetotheinteractionat
a site on the receptor distinct from the MPEP binding site
(Figure 9). Slight inhibition of radioligand binding at
higher concentrations may indicate some interaction
b e t w e e nt h eM P E Ps i t ea n dt h ep u t a t i v es i t eo fa c t i o no f
these PAMs.
A neutral allosteric ligand or silent allosteric mod-
ulator (SAM) binds to an allosteric site but does not
have positive or negative allosteric modulator activity
when measuring a defined response. However, a SAM
competesforbindingwithPAMsandNAMsandthere-
by blocks the effects of positive and negative allosteric
modulators without affecting the action of the or-
thosteric ligand through its binding to an allosteric
site (10, 23). Our laboratory previously reported that
the neutral ligand 5-MPEP binds to the same site as its
analogueMPEPandisabletoinhibitthefunctionofthe
NAM MPEP as well as PAMs such as VU-29 and
CPPHA (14, 23). Interestingly, 5-MPEP causes a com-
petitive inhibition of VU-29 activity, whereas it induces
a noncompetitive blockade of CPPHA function, pro-
vidingfurtherevidenceformultiplemodulatorysiteson
mGlu5, and distinct sites of action for MPEP-like
compoundsandCPPHA.Tofurthertestthehypothesis
that the novel benzamide class of mGlu5 PAMs de-
scribed hereacts atasitethatisdistinct fromtheMPEP
site, we utilized the SAM 5-MPEP as a tool to investi-
gate its effects on VU0357121 activity in two separate
assays.First,weexamined5-MPEPactivityontheCRC
of VU0357121-induced potentiation of glutamate-in-
duced increases in calcium mobilization. The mGlu5-
expressing HEK293 cells were treated with fixed con-
centrations (333 nM to 10 μM) of 5-MPEP or vehicle
and increasing concentrations of VU0357121, followed
by the addition of an EC20 concentration of glutamate.
Interestingly, in this kinetic assay 5-MPEP induces
progressive rightward shifts and reductions in the max-
imal response to VU0357121 potentiation of glutamate
responses (Figure 10A), suggesting that 5-MPEP is
likely to block the response to VU0357121 by a non-
competitive mechanism of action. To further explore
the interaction between these allosteric modulators in
an end-point assay, we performed phosphoinositide
(PI)hydrolysisstudiestomeasuretheeffectsof5-MPEP
on the VU0357121 agonist CRC. mGlu5-express-
ing HEK293 cells loaded with [
3H]myo-inositol were
treated with vehicle or a fixed concentration (10 μM)
of 5-MPEP, followed by various concentrations of
VU0357121. The resulting radiolabeled phosphoino-
sitides were measured and normalized to the response
elicited by 1 mM glutamate. Consistent with our find-
ingsinthecalciumassay,thisconcentrationof5-MPEP
Figure7. StructuresandSARofmGlu5PAMsfromInitialLibrary
Synthesis. (A) Diverse subset of synthetic analogues representative
of the comprehensive SAR observed during lead optimization
showing EC50 potency and Glumax efficacy values. (B) Summary
of observed SAR around VU0357121 showing western alkyl and
eastern aryl amide functional handles.r2010 American Chemical Society 708 DOI: 10.1021/cn100051m|ACS Chem. Neurosci. (2010), 1, 702–716
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caused a rightward shift in the VU0357121 CRC,
coupled with a decrease in maximal potentiation
(Figure 10B). As a control, we also investigated the
effects of the same concentration of 5-MPEP on the
VU-29 agonist curve. 5-MPEP (10 μM) induced a 20-
fold parallel rightward shift of the VU-29 CRC at a
magnitude consistent with the binding affinity for
5-MPEP (Ki = 388 ( 48 nM) and with the effect ob-
served in the kinetic assay. These data are consistent
withour previousstudiesandsuggestthat5-MPEPacts
in a competitive manner with VU-29 ((14)d a t an o t
shown).Thesefindingsareconsistentwithourhypothe-
sis that the benzamide class of mGlu5 PAMs acts at an
allosteric site other than the MPEP site and provide
further evidence that there is a functional interaction
between these two sites.
VU0357121 and Analogues Do Not Possess
mGlu5 NAM Activity
Studies with previousseries ofmGlu5 allostericmod-
ulators reveal that slight structural changes within a
seriescanleadtostrikingchangesinthemodesofmGlu5
pharmacologyofthesecompounds(PAMtoNAMand
NAM to PAM) (Figure 11). In fact, close analogues of
thefirstmGlu5PAMdescribed,DFB, displayeda wide-
rangeofmodesofpharmacologywithonlyslightstructural
Figure 8. Novel PAMs are selective for mGlu5 as compared to other subtypes. Despite weak inhibition of glutamate responses at mGlu1,
VU0357121 does not have PAM activity at other mGluR subtypes. Concentration-response relationships were generated by adding a fixed
concentration (30 μM) of test compound to cells expressing the specific mGluR subtype, followed by increasing concentrations of agonist.
Concentration-response curves were generated by nonlinear curve fitting. Data were obtained from three separate experiments, each
performed in duplicate or triplicate, and areexpressed asthemean (SEM. Data werenormalized tothe average maximum response obtained
from each experiment as determined by a maximum concentration of agonist.
Figure 9. Unlike MPEP, test compounds do not displace radioli-
gand binding. These novel PAMs have no effect on radioligand
binding at concentrations necessary for their function. Membranes
preparedfromHEKcellsexpressingmGlu5wereincubatedwiththe
radiolabeled MPEP analogue [
3H] methoxyPEPy (2 nM final con-
centration in 50 mM Tris and 0.9% NaCl, pH 7.4) for 60 min at
room temperature in the presence of varying concentrations of test
compound. Equilibrium bindingwasterminatedbyrapidfiltration.
Dataareplottedasapercentageoftotal[
3H]methoxyPEPybinding.
Data were obtained from three separate experiments, each per-
formed in triplicate, and are expressed as the mean ( SEM.r2010 American Chemical Society 709 DOI: 10.1021/cn100051m|ACS Chem. Neurosci. (2010), 1, 702–716
pubs.acs.org/acschemicalneuroscience Article
changes (10). Replacement of the 3,30-diF with a 3,30-
diOMe, DOMEB 14, provided an equipotent mGlu5
NAM, while the 3,30-diCl congener, DCB 15,w a st h e
first neutral mGlu5 ligand. Subsequently, a series of
mGlu5 partial antagonists 16 and 17 have also led to
neutral ligands such as 5-MPEP 18 (23). More re-
cently, another mGlu5 partial antagonist 5-PEP 20
wasconvertedintoapotent,fullNAMbytheaddition
of a methyl group in the 3-position 19;i nc o n t r a s t ,
addition of either a 4-methyl group 21 or an amino-
methyl moiety 22 afforded potent mGlu5 PAMs
(Figure 11). Similar switches in the mode of mGlu5
pharmacology have been noted in multiple mGlu5
NAM series and in the ADX mGlu5 PAM ser-
ies (15, 24, 25). Notably, this has only been observed
in MPEP site allosteric ligands and never observed in
thenon-MPEPsiteCPPHAseries.Toavoidpotential
metabolites in vivo that might possess switches in the
mode of pharmacology, it is imperative to establish
whether subtle structural changes in compounds in
this series of non-MPEP site ligands have a similar
propensity to display fundamentally different modes
of pharmacology.
Therefore, these compounds were also screened in a
manner to identify NAMs or noncompetitive antago-
nistsofmGlu5.Fortheantagonistscreen,wedetermined
whether the test compounds could inhibit the effect
of glutamate on mGlu5-expressing HEK293 cells. The
calcium mobilization assay was performed as de-
scribed above, with cells being treated with test com-
pounds at a fixed concentration of 10 μM, except that
they were stimulated with a submaximal concentra-
tionofglutamate(∼EC80).Incontrasttotheblockade
induced by the mGlu5 NAM MPEP, VU0357121 and
analogues did not inhibit the effect of glutamate on
mGlu5; in fact, the majority of compounds induced a
mild potentiation of the EC80 glutamate response
(Figure 12).
Identification of a Non-MPEP Site Neutral
Ligand
To date, the only known neutral allosteric ligands
or SAMs for mGlu receptors are ligands at the MPEP
site on mGlu5. To expand our investigation of putative
non-MPEPallostericsitesonmGlu5, itwouldbehelpful
tohaveaneutralligandthatactsatadifferentsiteonthe
receptorandpossiblyatthesamesiteasVU0357121.We
utilized the benzamide analogues that were synthesized
earlier to determine whether any neutral ligands were
present among these compounds. To screen our com-
pounds for this activity, we determined their ability to
block the VU0357121-induced potentiation of mGlu5-
mediatedresponsestoglutamate.Toaccomplishthis,we
Figure 10. Neutral ligand 5-MPEP causes rightward shifts and
decreases in the maximal response to VU0357121-mediated poten-
tiationofglutamate-inducedcalciummobilization,aswellaseffects
of VU0357121 on PI hydrolysis. (A) Increasing concentrations of
5-MPEP induce progressive rightward shifts and decreases in the
maximal potentiation by VU0357121 on glutamate-induced cal-
cium flux, indicating a noncompetitive interaction between the two
allosteric compounds. Concentration-response relationships were
generated by incubating cells with increasing concentrations of
VU0357121 and either vehicle (9) or 5-MPEP, followed by stimu-
lation with EC20 glutamate. (B) 5-MPEP (10 μM) also induced a
rightward shift and decrease in the maximal response to
VU0357121-induced PI hydrolysis. In this assay, cells received
either vehicle (9) or 5-MPEP (10 μM, 4), followed by various
concentrations of VU0357121, and the resulting phosphoinositides
were measured. Data for each assay were obtained from three
separate experiments, each performed in duplicate, and are ex-
pressed as the mean ( SEM. Data were normalized to the average
maximum response obtained from each experiment as determined
byamaximalconcentrationofglutamate.Concentration-response
curves were generated by nonlinear curve fitting.
Figure 11. Structure of MPEP-site allosteric ligand chemotypes
that display modes of pharmacology switches with slight structural
modifications.r2010 American Chemical Society 710 DOI: 10.1021/cn100051m|ACS Chem. Neurosci. (2010), 1, 702–716
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againusedacalciumassay,butcellswerepretreatedwith
the test compound (10 μM) and VU0357121 (50 nM)
followed by stimulation with an EC20 concentration
of glutamate. Several compounds significantly inhi-
bited the PAM activity of VU0357121 (Figure 13), but
VU0365396 caused the most robust inhibition and was
therefore chosen for further characterization. Interest-
ingly, VU0365396 (30 μM) induced a parallel rightward
shift in the VU0357121 CRC (Figure 14A), suggest-
ing that this compound is a neutral ligand that acts
in a competitive manner at the same allosteric site as
VU0357121. In contrast, VU0365396 (30 μM) had no
effect on CPPHA-induced potentiation of mGlu5 re-
sponses (Figure 14B). The lack of effect on CPPHA
PAM activity was somewhat surprising but provides
clear evidence that these mGlu5 PAMs do not act at
the same site and raises the possibility that these sites
may not interact functionally. However, it is possible
that limited affinity of the neutral ligand at its own site
or limited negative cooperativity led to a lack of effect
on CPPHA responses. Unfortunately, limitations with
solubility precluded studies with higher concentrations
of VU0365396.
Mutations Differentially Alter Responses to
VU0357121 and CPPHA
We previously reported the effects of single point
mutations in mGlu5 which can inhibit the responses of
mGlu5 to specific PAMs and NAMs (8, 14, 20). These
mutantsweretestedfortheirabilitytoalterresponsesto
VU0357121 (1 μM) in transiently transfected HEK293
cells using the calcium mobilization assay. Mutation of
the alanine at the 809 position of rat mGlu5 to a valine
(A809V/rmGlu5) reduces the binding and function of
MPEP and inhibits functional responses to PAMs that
act at the MPEP site, such as VU-29 (8, 14, 20) but has
no effect on responses to CPPHA (14). In contrast,
the F585I/rmGlu5 mutation inhibits the PAM activity
of CPPHA but has no effect on responses to VU-29
activity (14). We replicated these previous findings and
foundthattheresponsetoVU-29butnotCPPHAislost
in the A809V/rmGlu5 mutant, whereas the response to
CPPHA but not VU29 is lost in the F585I/rmGlu5
mutant (data not shown). Interestingly, we found that
the A809V/rmGlu5 mutation inhibited the ability of
VU0357121 to shift the glutamate concentration-
response curve (Figure 15A), whereas the response to
VU0357121wasnotalteredbytheF585I/rmGlu5muta-
tion (Figure 15B). The finding that the F585I mutation
was without effect is consistent with studies above
suggesting that CPPHA and VU0357121 do not act at
identical sites. The finding that the response was inhib-
ited by the A809V mutation is somewhat surprising in
light of the results from the molecular pharmacology
studies and further illustrates the complexity of the
relationshipsbetweenputativeallostericsitesonmGlu5.
In addition, these data highlight the fact that mutagen-
esis studies must be interpreted with caution. While
previous studies and the current data provide strong
evidencethatmultiplemGlu5modulatorsdonotbindto
identical binding sites, it is possible that they interact
with overlapping sites that share critical residues. Also,
intheabsenceofdirectstructuralinformationaboutthe
class C GPCRs, models of class C GPCR structure and
functional effects of specific mutations do not provide
Figure 12. Unlike MPEP, no benzamide analogues were able to
antagonize a submaximal (EC80) concentration of glutamate. HEK
cells were pretreated with a fixed concentration of test compound
(10 μM) or vehicle, followed by EC80 glutamate. Data were
normalized to the average maximal response obtained from each
experiment as determined by 100 μM glutamate. Data were
obtained from three separate experiments, each performed in
triplicate, and are expressed as the mean ( SEM.
Figure13. VU0365396isthefirstnon-MPEPsiteneutralallosteric
ligand. Several benzamide analogues, as well as the previously
identified neutral ligand 5-MPEP, significantly attenuate the
potentiation of mGlu5-mediated responses to glutamate by
VU0357121. VU0365396 induces the most robust inhibition of
VU0357121 effects (p < 0.01), and its chemical structure is shown
in the inset. The calcium mobilization assay was used to screen
benzamide analogues for neutral ligand activity. To establish the
level of VU0357121 potentiation, HEK cells expressing mGlu5
were pretreated with VU0357121 (50 nM), vehicle, and EC20
glutamate.Todeterminewhethertestcompoundscouldinhibitthe
effect of VU0357121, cells were treated with VU0357121 (50 nM)
and 5-MPEP (10 μM) or a benzamide analogue (10 μM) made up
in the same solution, followed by EC20 glutamate. Data were
normalized to the average maximal response obtained from each
experiment as determined by 100 μM glutamate. Data were
obtained from three separate experiments, each performed in
triplicate, and are expressed as the mean ( SEM. *p < 0.05,
**p < 0.01.r2010 American Chemical Society 711 DOI: 10.1021/cn100051m|ACS Chem. Neurosci. (2010), 1, 702–716
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definitiveinformationaboutthenatureofthebindingof
these ligands. However, the resultsofthese mutagenesis
studies combined with the current and previous mole-
cular pharmacology studies provide further evidence
that there is some interaction between the putative
binding sites of CPPHA, VU0357121, and the MPEP
binding site that are important for the action of
these structurally and functionally diverse allosteric
modulators.
In summary, using a functional HTS screen and
subsequent library synthesis approach, we have discov-
eredanovelseriesofhighlyselectivemGlu5PAMsanda
neutralligandthathavepropertiesthatsuggestthatthey
do not act as traditional MPEP site ligands. Also, our
results suggest that these compounds do not interact
with the receptor in a manner that is identical to that of
CPPHA. Our present and previous studies suggest the
presenceofdistinctallostericsitesormodesofactionfor
VU0357121, CPPHA, and MPEP-site ligands such as
VU-29.Ifthisisthecase,itisnotyetclearwhetherthese
sites physically overlap or whether they are physically
distinct but functionally interact through allosteric me-
chanisms. While the weight of evidence suggests that
these allosteric modulators interact with different bind-
ingsites,itisimportanttoconsiderthatuntilthebinding
pockets for each ofthese compoundsisfully elucidated,
it is impossible to definitively determine whether these
compounds bind to the same or distinct binding sites.
For instance, if the interaction of each of the allosteric
modulators at mGlu5 has not reached equilibrium, this
could influence the nature of the shifts in PAM CRCs
that are observed with neutral ligands (26). Also, the
lack of apparent binding to the MPEP site could be
explained by very high cooperativity such that occu-
pancy of less than 0.1% of the receptor leads to full
potentiation of the response to glutamate. Finally,
allosteric ligands could bind to a single monomer in
a functional homodimer, and this could impact the
pharmacological profile. While unlikely, it is important
to consider these possibilities until we have definitive
Figure 14. VU0365396 competitively inhibits VU0357121 function but has no effect on CPPHA activity. (A) VU0365396 induces a parallel
rightward shift in the VU0357121 concentration-response curve, indicating a competitive interaction between the two compounds. Cells
expressingmGlu5weretreatedwithincreasingconcentrationsofVU0357121andeithervehicle(9)orVU0365396(30μM,4)followedbyEC20
glutamate.(B)ThecalciummobilizationresponseproducedwhenmGlu5-expressingHEK293cellsweretreatedwithincreasingconcentrations
ofCPPHAandEC20glutamatedonotdifferintheabsence(9)orpresence(4)ofVU0365396(30μM).Datawereobtainedfromthreeseparate
experiments, each performed in duplicate, and are expressed as the mean ( SEM. Data were normalized to the average maximum response
obtainedfromeachexperimentasdeterminedby100μMglutamate.Concentration-responsecurvesweregeneratedbynonlinearcurvefitting.
Figure 15. Mutations that inhibit the function of MPEP/VU-29 also inhibit VU0357121 function, but mutations that inhbit CPPHA activity
do not. The ability of VU0357121 (1 μM) to function when specific mGlu5 mutants were transiently expressed in HEK cells was assessed. The
calcium mobilization assay was used to determine whether the mGlu5 PAM was able to enhance the glutamate concentration-response
relationship at either the A809V/rmGlu5 mutant or the F585I/rmGlu5 mutant. The A809V mutation led to an inhibition of VU0357121
activity (A), whereas the F585I mutation had no effect on its function (B). Concentration-response relationships were generated by adding
either vehicle or a fixed concentration (1 μM) of VU0357121 to transiently transfected HEK cells, followed by increasing concentrations of
glutamate.Datawereobtainedfromthreeseparateexperiments,eachperformedinduplicate,andareexpressedasthemean(SEM.Datawere
normalized to the average maximum response obtained from each experiment as determined by 100 μM glutamate.r2010 American Chemical Society 712 DOI: 10.1021/cn100051m|ACS Chem. Neurosci. (2010), 1, 702–716
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structural information on mGlu5 and the allosteric
binding sites.
Methods
Compounds
The Vanderbilt High Throughput Screening Center com-
pound collection was obtained from ChemBridge Corpora-
tion (San Diego, CA) and ChemDiv, Inc. (San Diego, CA).
L-Glutamate and MPEP were obtained from Tocris Bio-
science(Ellisville,MO).[
3H]methoxyPEPywasobtainedfrom
American Radiolabeled Chemicals, Inc. (St. Louis, MO).
CPPHA(17)and5-MPEP(23)weresynthesizedaspreviously
described.
Chemical Synthesis
General. All NMR spectra were recorded on a Bruker 400
MHz instrument.
1H chemical shifts are reported in δ values
in ppm relative to CDCl3 at 7.27 ppm. Data are reported as
follows:chemicalshift,multiplicity(s=singlet,d=doublet,
t = triplet, q = quartet, br = broad, and m = multiplet),
coupling constant (Hz), and integration. Low resolution
mass spectra were obtained on an agilent 1200 series 6130
mass spectrometer. Analytical thin layer chromatography
was performed on Analtech silica gel GF 250 μm plates.
Analytical HPLC was performed on an agilent 1200 series.
Preparative purification was performed on a combi-flash
companion. Solvents for extraction, washing, and chroma-
tography were of HPLC grade. All reagents were pur-
chased from Aldrich Chemical Co. and were used without
purification.
VU0001850
To a solution of 2-amino-5-chloro-pyridine (129 mg,
1.0 mmol) in dichloromethane (5 mL) was added N,N-diiso-
propylethylamine(174μL,1.0mmol),4-propoxybenzoicacid
(180 mg, 1.0 mmol), and chlorodipyrrolidinocarbenium hex-
afluorophosphate (PyClU) (365 mg, 1.0 mmol) under an
argonatmosphere.Thereactionwasstirredfor1hatambient
temperature. Water (5 mL) was added and the reaction
mixturefilteredthroughanISPphaseseparator.Theorganics
were concentrated and purified by Flash Column Chroma-
tography(hexane/ethyl acetate, gradient = 50% to100%) to
affordthebenzamideasanoffwhitecrystallinesolid(110mg,
38%) upon concentration.
1H NMR (400 MHz, CDCl3) δ
8.10 (d, J=8.8, 2H), 8.00 (s, 1H), 7.72 (d, J=8.8, 1H), 6.98
(d, J=8.8, 2H), 6.51 (d, J=8.8, 1H), 4.00 (t, J=6.8, 6.4,
2H), 1.90-1.77 (m, 2H), 1.06 (t, J=7.2, 7.4, 3H); LC-MS
(214 nM) 2.0 min, m/z 292.1.
VU0040237
To a solution of 2-fluoroaniline (101 μL, 1.0 mmol) in
dichloromethane (5 mL) was added N,N-diisopropylethyl-
amine (174 μL, 1.0 mmol) and 4-butoxybenzoyl chloride
(189 μL, 1.0 mmol), and the reaction was stirred for 45 min
at ambient temperature. Saturated sodium bicarbonate
(1 mL) was added and the reaction mixture filtered through
an ISP phase separator. The organics were concentrated and
purified by Gilson HPLC to afford the benzamide as a white
crystallinesolid(280mg,97%)uponconcentration.
1HNMR
(400 MHz, CDCl3) δ 8.00(bs, 1H), 7.88-7.86 (d, J = 8, 2H),
7.20-7.04(m,4H),7.01-6.99(d,J=8,2H),4.04(t,J=6.8,
6.4, 2H), 1.84-1.77 (m, 2H), 1.56-1.47 (m, 2H), 1.00 (t, J =
7.6, 7.2, 3H); LC-MS (214 nM) 2.0 min, m/z 288.2.
VU0365396
To a solution of 2,6-difluoroaniline (101 μL, 1.0 mmol) in
dichloromethane (5 mL) was added N,N-diisopropylethyl-
amine (174 μL, 1.0 mmol) and 4-butoxybenzoyl chloride
(189 μL, 1.0 mmol), and the reaction was stirred for 45 min at
ambient temperature. Saturated sodium bicarbonate (1 mL)
was added and the reaction mixture filtered through an ISP
phaseseparator.Theorganicswereconcentratedandpurified
byGilsonHPLCtoaffordthebenzamideasawhitecrystalline
solid (285 mg, 93%) upon concentration;.
1H NMR (400
MHz,CDCl3)δ7.85(d,J=8.8,2H),6.99-6.88(m,5H),4.04
(t, J = 6.4, 6.4, 2H), 1.84-1.77 (m, 2H), 1.57-1.47 (m, 2H),
0.99(t,J=7.6,7.2,3H);LC-MS(214nM)2.0min,m/z306.2.
VU0357121
To a solution of 2,4-difluoroaniline (101 μL, 1.0 mmol) in
dichloromethane (5 mL) was added N,N-diisopropylethyla-
mine (174 μL, 1.0 mmol) and 4-butoxybenzoyl chloride
(189 μL, 1.0 mmol), and the reaction was stirred for 45 min
at ambient temperature. Saturated sodium bicarbonate (1 mL)
was added and the reaction mixture filtered through an ISP
phase separator. The organics were concentrated and purified
by Gilson HPLC to afford the benzamide as a white crystalline
solid (290 mg, 95%) upon concentration.
1H NMR (400 MHz,
CDCl3) δ 8.10 (d, J=8, 2H), 7.01-6.95 (m, 5H), 4.06 (t, J =
6.4, 6.4, 2H), 1.85-1.75 (m, 2H), 1.57-1.46 (m, 2H), 1.00 (t,
J =7 . 6 ,7 . 2 ,3 H ) ;L C - M S( 2 1 4n M )2 . 0m i n ,m/z 306.2.
VU0125936
To a solution of 2-amino-5-chloro-pyridine (129 mg, 1.0
mmol) in dichloromethane (5 mL) was added N,N-diisopro-
pylethylamine (174 μL, 1.0 mmol) and 4-butoxybenzoyl chlor-
ide (189 μL, 1.0 mmol), and the reaction was stirred for 45 min
at ambient temperature. Saturated sodium bicarbonate (1 mL)
was added and the reaction mixture filtered through an ISP
phase separator. The organics were concentrated and purified
by Gilson HPLC to afford the benzamide as a white crystalline
solid (260 mg, 86%) upon concentration.
1HNMR (400 MHz,
CDCl3)δ8.02(s,1H),7.21(d,J=8,2H),7.75(d,J=8.8,2H),
6.85 (d, J =8 . 8 ,2 H ) ,6 . 4 6( d ,J = 8.8, 1H), 4.50 (bs, 1H), 3.98
(t, J = 6.4, 6.4, 2H), 1.80-1.73 (m, 2H), 1.51-1.46 (m, 2H),
0.98(t, J= 7.6, 7.4, 3H); LC-MS (214 nM) 2.0 min, m/z305.2.
Cell Culture
HEK293 cells stably expressing rat mGlu5 were grown in
standard Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), 2 mM
L-glutamine, 20 mM HEPES, 0.1 mM nonessential amino
acids, 1 mM sodium pyruvate, 1  antibiotic-antimycotic (all
fromInvitrogen,Carlsbad,CA),and500μg/mLG418sulfate
fromMediatech,inc.(Manassas,VA),at37C inthe presence
5% CO2.
Fluorescence-Based Calcium Flux Assay
Screening assays were completed within Vanderbilt Uni-
versity’s HTS laboratory and were performed as previously
described (18-20). Hits from the primary screen including
VU0001850, VU0003712, and VU0040237 were confirmed
by testing for concentration-dependent activity on mGlu5
over a range of 4 log units including 10 μM, as depicted in
Figure 2. Compounds were serially diluted 1:3 into 10-pointr2010 American Chemical Society 713 DOI: 10.1021/cn100051m|ACS Chem. Neurosci. (2010), 1, 702–716
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concentration-response curves (30 μM-1 nM final), trans-
ferred to daughter plates using the Echo acoustic plate refor-
matter (Labcyte, Sunnyvale, CA), and tested as described in
the primary screen except that test compounds were applied
for 300 s followed by addition of EC20 concentrations of
glutamate.AllothermGlu5calciumassayswereperformedin
the following manner. Human embryonic kidney (HEK293)
cells stably expressing mGlu5 were plated in black-walled,
clear-bottomed, poly-D-lysine coated, 96-well plates (BD Bio-
coat, Bedford, MA) in 100 μL glutamate/glutamine-free
medium (glutamine-free DMEM plus 10% dialyzed fetal
bovine serum; Invitrogen) at 30,000 cells per well at least 24 h
prior to the assay. Cells were incubated overnight at 37 Ci n
t h ep r e s e n c eo f5 %C O 2. The next day, the medium was
manually removed, and the cells were incubated with 50 μL
of Hank’s balanced salt solution (HBSS; Invitrogen) contain-
ing 2.5 mM Probenecid, 20 mM HEPES, and 2 μMc a l c i u m -
sensitive Fluo4-AM dye (Molecular Probes) at pH 7.4 for 45
minat37Cand5%CO 2.The dyewasremoved, and60μLof
assay buffer containing HBSS, 20 mM HEPES, and 2.5 mM
Probenecid (Sigma), adjusted to pH 7.4, was added. Ten min-
utes later, cells were placed into the Flexstation II (Molecular
Devices, Sunnyvale, CA) where they received 20 μLo fv e h i c l e
or test compound diluted into assay buffer to a 4  stock
after 19 s, followed by 20 μL of glutamate diluted to a 5 
stock at 109 s. Specifically, for the PAM screen, cells received a
fixed concentration of test compound (10 or 1 μM) or vehicle,
followed by a concentration of glutamate that evoked about a
20% response as compared to the maximum glutamate re-
sponse (EC20). To screen for antagonists, cells received a fixed
concentration of test compound (10 μM) or vehicle, followed
by a concentration of glutamate, which elicited a response
that was 80% of the maximum glutamate response (EC80). To
determine the concentration-response relationships of the
mGlu5 PAMs, cells received increasing concentrations of the
test compound, followed by stimulation with EC20 glutamate.
To determine the effect of the mGlu5 PAMs on the glutamate
dose-response relationship, cells received the test compound
(12.5 μM) or vehicle followed by increasing concentrations of
glutamate (with a top concentration of 100 μM). To screen for
neutral allosteric site ligand activity, cells received the test
compound (10 μM) or vehicle and VU0357121 (50 nM) made
u pi nt h es a m e4   solution followed by EC20 glutamate. To
determine the effect of the neutral ligands on mGlu5 PAM
activity, cells received increasing concentrations of 5-MPEP
(333 nM to 10 μM), a fixed concentration of VU0365396
(30 μM), or vehicle prepared in the same 4  solution as
increasing concentrations of VU0357121 or CPPHA, followed
by EC20 glutamate. Fluorescence was measured for a total of
160 s per well for each assay. Data were transformed and fit
withGraphPadPrism(GraphPadSoftware,Inc.,LaJolla,CA)
to determine EC50 values. For the neutral ligand screen, data
were analyzed by a one-way ANOVA with comparison to the
EC20 þ VU0357121 þ vehicle control group using a Dunnett’s
test. Calculations were performed using GraphPad Prism.
Selectivity Studies
Rat mGlu1. HEK293 cells stably expressing mGlu1
were cultured and assayed as described above for mGlu5-
expressing cells. During the calcium fluorescence assay, cells
were incubated with vehicle or test compound at a fixed
concentration of 30 μM, followed by increasing concentra-
tions of glutamate.
Rat mGlu Receptors 2, 3, 4, 7, and 8, and Human mGlu6.
Compound activity at the group II and III mGlu receptors
was assessed using thallium flux through G-protein-coupled
inwardly rectifying potassium (GIRK) channels, a method
that has been described in detail (21). These cell lines were
grown ingrowth mediacontaining45%DMEM,45%F-12,
10% FBS, 20 mM HEPES, 2 mM L-glutamine, antibiotic/
antimycotic, nonessential amino acids, 700 μg/mL G418,
and 0.6 μg/mL puromycin at 37 C in the presence of 5%
CO2. Briefly, GIRK cells expressing the mGluR subtype 2, 3,
4, 6, 7, or 8 were plated into 384-well, black-walled, clear-
bottom poly-D-lysine coated plates at a density of 15,000
cells/20 μL/well in assay medium and incubated overnight at
37 C in the presence of 5% CO2. The following day, the
medium was removed from the cells, and 20 μL/well of
1 μM concentration of the indicator dye Fluozin2-AM
(Invitrogen,Carlsbad,CA)inassaybufferwasadded.Cells
were incubated for 1 h at room temperature, and the dye
was replaced with 20 μL/well of assay buffer. For these
assays, vehicle or test compound (2  final concentration)
was added, followed by varying concentrations of gluta-
mate2.5minlaterusingFDSS6000.Glutamatewasdiluted
in thallium buffer (125 mM sodium bicarbonate, 1 mM
magnesium sulfate, 1.8 mM calcium sulfate, 5 mM glucose,
12mMthalliumsulfate,and10mMHEPES)at5 thefinal
concentration to be assayed. Data were analyzed as pre-
viously described (21).
Radioligand Binding Assay
The allosteric antagonist MPEP analogue [
3H]methoxy-
PEPy was used to evaluate the ability of test compounds to
interact with the MPEP site on mGlu5 (22). Membranes were
prepared from rat mGlu5 HEK293 cells (23). Compounds
weredilutedinassaybuffer(50mMTris/0.9%NaCl,pH7.4)
toa 5  stock, and 100 μL of the testcompound was added to
each well of a 96 deep-well assay plate. Three hundred
microliter aliquots of membranes diluted in assay buffer
(20 μg/well) were added to each well. One hundred microliters
of [
3H]methoxyPEPy (2 nM final concentration) was added,
and the reaction was incubated at room temperature for 1 h
with shaking. After the incubation period, the membrane-
bound ligand was separated from free ligand by filtration
through glass-fiber 96-well filter plates (Unifilter-96, GF/B,
PerkinElmer Life and Analytical Sciences, Boston, MA). The
contents of each well were transferred simultaneously to the
filter plate and washed 3-4 times with assay buffer using a cell
harvester (Brandel Cell Harvester, Brandel Inc., Gaithersburg,
MD). Forty microliters of scintillation fluid was added to each
well and the membrane-bound radioactivity determined by
scintillation counting (TopCount, PerkinElmer Life and Ana-
lytical Sciences). Nonspecific binding was estimated using
5 μM MPEP. Concentration-response curves were generated
using a four parameter logistical equation in GraphPad Prism.
Phosphoinositide (PI) Hydrolysis Assay
HEK cells expressing mGlu5 were plated at 150,000 cells
per well in the glutamate/glutamine-free assay medium de-
tailedabovein24-wellplates24hpriortoassay.Sixteenhoursr2010 American Chemical Society 714 DOI: 10.1021/cn100051m|ACS Chem. Neurosci. (2010), 1, 702–716
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prior to experiments, the cells received new assay media
containing 1 μCi/mL [
3H]myo-inositol (Perkin-Elmer LAS).
On the day of the assay, cells were treated with either vehicle
or a fixed concentration of 5-MPEP (10 μM) in HBSS
(containing 110 mM NaCl, 5.4 mM KCl, 1.8 mMCaCl2,
1 mM MgCl2, 25 mM glucose, and 58.4 mM sucrose at pH
7.4) supplemented with 20 mM HEPES and 30 mM LiCl,
replacing the [
3H]myo-inositol-containing media. Following
vehicleorneutralligandaddition,arangeofconcentrationsof
VU0357121 were added, and cells were incubated for 1 h at
37 C and 5% CO2. The accumulation of phosphoinositides
was terminated by aspiration of ligand-containing buffer,
followed by the addition of 10 mM formic acid (1 mL/well)
and incubation for 1 h at room temperature to ensure the
extraction of phosphoinositides. Columns packed with a
1 mL bed of AG 1-X8 Resin 100-200 mesh anion-ex-
changeresin(formateform)(Bio-Rad;Hercules,CA)were
washed twice with 10 mL of water. Following the water
washes, the entire 1 mL sample volumes were added to the
columns, avoiding the transfer of any cells. Columns were
washed with 10 mL of water, followed by 10 mL of 5 mM
myo-inositol. Total phosphoinositides (PIs) were eluted
with 10 mL of 0.1 M formic acid/0.2 M ammonium
formate into vials containing 3a70B liquid scintillation
cocktail (Research Products International; Elk Grove
Village, IL), and the radioactivity was measured by liquid
scintillation counting. Following use, columns were re-
generated with 10 mL of 0.1 M formic acid/1 M ammo-
nium formate and washed with 30 mL of water. Data were
corrected for baseline levels, normalized to the maximum
response to 1 mM glutamate, and analyzed with Graph-
Pad Prism to determine EC50 values.
Transient Transfections
HEK293cellsweregrowninstandardDulbecco’smodified
Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 20 mM HEPES, and 1  antibiotic-
antimycotic. Cells were collected and plated in 100 mm
tissue culture dishes (Costar; Corning Life Sciences, Acton,
MA)innormalgrowthmediumovernightbeforetransfection.
The next day, cells were transiently transfected with mutant
forms of mGlu5 cDNA using FuGENE 6 (Roche Applied
Science, Indianapolis, IN) according to the manufacturer’s
instructions (2 μg of DNA, 24 μL of FuGENE 6, and 776 μL
of Opti-MEM (Invitrogen, Carlsbad, CA)). The next day,
cells were plated in black-walled, clear-bottomed, 96-well
plates(Costar;CorningLifeSciences,Acton,MA)pretreated
with poly-D-lysine (Sigma, St. Louis, MO). Calcium assays
were performed on FlexStation II, as described above, on the
followingdaytostudytheeffectofVU0357121(1μM) onthe
glutamate concentration-response activity of each mutant.
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GIRK, G-protein regulated inwardly rectifying potassium
channel; [
3H]methoxy-PEPy, [
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